Experiment reveals that decreasing CSF1R in myeloid cells shows minimal effect on chronic lymphocytic leukemia, indicating a need for stronger therapeutic approaches.
Key Points
Reducing csf1r expression in myeloid cells has minimal impact on leukemia progression, and overall survival was similar to controls.
Mice with lower csf1r levels demonstrated decreased leukemia during early disease stages, but this effect diminished later on.
Analysis involved creating CLL mice with csf1r haploinsufficiency to assess changes in leukemic progression and myeloid support.
These findings suggest that targeting CSF1R may require more robust macrophage depletion or combination strategies for effective therapy.